Vol 71, No 5 (2020)
Original paper
Published online: 2020-08-03

open access

Page views 1669
Article views/downloads 982
Get Citation

Connect on Social Media

Connect on Social Media

miRNA-16-5p inhibits the apoptosis of high glucose-induced pancreatic β cells via targeting of CXCL10: potential biomarkers in type 1 diabetes mellitus

Xiaoyan Gao1, Shumiao Zhao2
Pubmed: 32797474
Endokrynol Pol 2020;71(5):404-410.

Abstract

Introduction: We aimed to elucidate the relationship between CXC chemokine ligand 10 (CXCL10) and miR-16-5p, and their functions on the biological behaviour of type 1 diabetes mellitus (T1DM).

Material and methods: The GSE72492 dataset from the GEO database was used to analyse gene expression. We discovered that CXCL10 was highly expressed in T1DM patients. The up-stream miRNA was predicted by Targetscan website. Low glucose (2.8 mmol/L) and high glucose (HG, 16.7 mmol/L) were utilised to treat β-TC-tet (pancreatic β cell) cells to form the model. The direct interaction between miR-16-5p and CXCL10 was verified by a dual-luciferase reporter assay. Real-time quantitative PCR (qRT-PCR) and western blotting analyses were used to detect RNA and protein expression. CCK8 and flow cytometry were used to detect cell proliferation and apoptosis.

Results: We discovered that CXCL10 was highly expressed in T1DM patients. MiR-16-5p, which was lowly expressed in T1DM patients, was verified the upstream regulatory miRNA of CXCL10. The facilitating influence of miR-16-5p up-regulation on the proliferation of HG-induced β-TC-tet cells was reversed by CXCL10 over-expression, while the knockdown results were opposite. More importantly, the restraining impact of miR-16-5p high expression on the apoptosis of HG-induced β-TC-tet cells was accelerated by CXCL10 over-expression. Correspondingly, the level of Bcl-2 was enhanced while the levels of Bax and Cleaved Caspase-3 were lowered by miR-16-5p mimic, which were reversed by CXCL10 over-expression in HG-treated β-TC-tet cells.

Conclusions: Our data offered evidence that miR-16-5p implicated in T1DM cell proliferation and apoptosis through targeting CXCL10, which might provide novel therapeutic information for T1DM. 

Article available in PDF format

View PDF Download PDF file

References

  1. Yi Bo, Huang G, Zhou Z. Different role of zinc transporter 8 between type 1 diabetes mellitus and type 2 diabetes mellitus. J Diabetes Investig. 2016; 7(4): 459–465.
  2. Novotna M, Podzimek S, Broukal Z, et al. Periodontal Diseases and Dental Caries in Children with Type 1 Diabetes Mellitus. Mediators Inflamm. 2015; 2015: 379626.
  3. Rak K, Bronkowska M. Immunomodulatory Effect of Vitamin D and Its Potential Role in the Prevention and Treatment of Type 1 Diabetes Mellitus-A Narrative Review. Molecules. 2018; 24(1).
  4. Zhang L, Zhang Q. Glycated Plasma Proteins as More Sensitive Markers for Glycemic Control in Type 1 Diabetes. Proteomics Clin Appl. 2020; 14(2): e1900104.
  5. Chellappan DK, Sivam NS, Teoh KX, et al. Gene therapy and type 1 diabetes mellitus. Biomed Pharmacother. 2018; 108: 1188–1200.
  6. Fu S, Li L, Deng S, et al. Effectiveness of advanced carbohydrate counting in type 1 diabetes mellitus: a systematic review and meta-analysis. Sci Rep. 2016; 6: 37067.
  7. Bjerg L, Hulman A, Charles M, et al. Clustering of microvascular complications in Type 1 diabetes mellitus. J Diabetes Complications. 2018; 32(4): 393–399.
  8. Garcia-Contreras M, Brooks RW, Boccuzzi L, et al. Exosomes as biomarkers and therapeutic tools for type 1 diabetes mellitus. Eur Rev Med Pharmacol Sci. 2017; 21(12): 2940–2956.
  9. He J, Lian C, Fang Y, et al. Effect of CXCL10 receptor antagonist on islet cell apoptosis in a type I diabetes rat model. Int J Clin Exp Pathol. 2015; 8: 14542–14548.
  10. Lee JH, Kim B, Jin WJ, et al. Pathogenic roles of CXCL10 signaling through CXCR3 and TLR4 in macrophages and T cells: relevance for arthritis. Arthritis Res Ther. 2017; 19(1): 163.
  11. Fan Y, Zhang W, Wei H, et al. Hepatic NK cells attenuate fibrosis progression of non-alcoholic steatohepatitis in dependent of CXCL10-mediated recruitment. Liver Int. 2020; 40(3): 598–608.
  12. Antonelli A, Ferrari SM, Giuggioli D, et al. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev. 2014; 13(3): 272–280.
  13. Chen Ju, Ye X, Pitmon E, et al. IL-17 inhibits CXCL9/10-mediated recruitment of CD8 cytotoxic T cells and regulatory T cells to colorectal tumors. J Immunother Cancer. 2019; 7(1): 324.
  14. Homann D. Back From the Brink: The Uses of Targeting the CXCL10:CXCR3 Axis in Type 1 Diabetes. Diabetes. 2015; 64(12): 3990–3992.
  15. Ahmadi Z, Arababadi MK, Hassanshahi G. CXCL10 activities, biological structure, and source along with its significant role played in pathophysiology of type I diabetes mellitus. Inflammation. 2013; 36(2): 364–371.
  16. Pan W, Zhang Y, Zeng C, et al. miR-192 is upregulated in T1DM, regulates pancreatic β-cell development and inhibits insulin secretion through suppressing GLP-1 expression. Exp Ther Med. 2018; 16(3): 2717–2724.
  17. Lakhter AJ, Pratt RE, Moore RE, et al. Beta cell extracellular vesicle miR-21-5p cargo is increased in response to inflammatory cytokines and serves as a biomarker of type 1 diabetes. Diabetologia. 2018; 61(5): 1124–1134.
  18. Assmann TS, Recamonde-Mendoza M, De Souza BM, et al. MicroRNA expression profiles and type 1 diabetes mellitus: systematic review and bioinformatic analysis. Endocr Connect. 2017; 6(8): 773–790.
  19. Assmann TS, Recamonde-Mendoza M, Costa AR, et al. Circulating miRNAs in diabetic kidney disease: case-control study and in silico analyses. Acta Diabetol. 2019; 56(1): 55–65.
  20. Yue Y, Tang Y, Tang J, et al. Maternal infection during pregnancy and type 1 diabetes mellitus in offspring: a systematic review and meta-analysis. Epidemiol Infect. 2018; 146(16): 2131–2138.
  21. Herold KC, Vignali DAA, Cooke A, et al. Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol. 2013; 13(4): 243–256.
  22. DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet. 2018; 391(10138): 2449–2462.
  23. Antonelli A, Ferrari SM, Corrado A, et al. CXCR3, CXCL10 and type 1 diabetes. Cytokine Growth Factor Rev. 2014; 25(1): 57–65.
  24. Homann D. Back From the Brink: The Uses of Targeting the CXCL10:CXCR3 Axis in Type 1 Diabetes. Diabetes. 2015; 64(12): 3990–3992.
  25. Corrado A, Ferrari SM, Ferri C, et al. Type 1 diabetes and (C-X-C motif) ligand (CXCL) 10 chemokine. Clin Ter. 2014; 165(2): e181–e185.
  26. Christen S, Holdener M, Beerli C, et al. Small molecule CXCR3 antagonist NIBR2130 has only a limited impact on type 1 diabetes in a virus-induced mouse model. Clin Exp Immunol. 2011; 165(3): 318–328.
  27. Coppieters KT, Amirian N, Pagni PP, et al. Functional redundancy of CXCR3/CXCL10 signaling in the recruitment of diabetogenic cytotoxic T lymphocytes to pancreatic islets in a virally induced autoimmune diabetes model. Diabetes. 2013; 62(7): 2492–2499.
  28. Liu B, Shyr Yu, Cai J, et al. Interplay between miRNAs and host genes and their role in cancer. Brief Funct Genomics. 2018; 18(4): 255–266.
  29. Steiman-Shimony A, Shtrikman O, Margalit H. Assessing the functional association of intronic miRNAs with their host genes. RNA. 2018; 24(8): 991–1004.
  30. Liu Z, Wang Y, Wang L, et al. Long non-coding RNA AGAP2-AS1, functioning as a competitive endogenous RNA, upregulates ANXA11 expression by sponging miR-16-5p and promotes proliferation and metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2019; 38(1): 194.
  31. Schulthess FT, Paroni F, Sauter NS, et al. CXCL10 impairs beta cell function and viability in diabetes through TLR4 signaling. Cell Metab. 2009; 9(2): 125–139.
  32. Cai B, Ma M, Chen B, et al. MiR-16-5p targets SESN1 to regulate the p53 signaling pathway, affecting myoblast proliferation and apoptosis, and is involved in myoblast differentiation. Cell Death Dis. 2018; 9(3): 367.
  33. Sun Y, Xiong Y, Yan C, et al. Downregulation of microRNA-16-5p accelerates fracture healing by promoting proliferation and inhibiting apoptosis of osteoblasts in patients with traumatic brain injury. Am J Transl Res. 2019; 11(8): 4746–4760.
  34. Ren Yu, Huang W, Weng G, et al. LncRNA PVT1 promotes proliferation, invasion and epithelial-mesenchymal transition of renal cell carcinoma cells through downregulation of miR-16-5p. Onco Targets Ther. 2019; 12: 2563–2575.